Date of birth: 08/28/1977; Nationality: French
Researcher unique identifier: ORCID 0000-0001-8360-7497
Contribution to schistosomiasis: I discovered the Venus Receptor Kinase (VKR) family in the parasite Schistosoma mansoni and studied their role in its reproduction and development. I developed the first microfluidic devices for studying parasite in dynamic and biomimetic environment (Mol. Biol. Parasitol. 2003 DOI, J. Biol. Chem 2004 DOI, R. Soc. Open Sci.DOI).
Contribution to chemical biology & protein therapeutic design: I contributed to the understanding of the HGF/SF-MET receptor activation determinants using chemical biology and biophysical approaches in collaboration with E. Gherardi’s team in Pavia (Italy). This knowledge enabled the design of a strong MET agonist (K1K1) with a broad field of applications in regenerative medicine. I am supervising its industrial development with the pharmaceutical company Boehringer Ingelheim International (Chem. Sci. 2015 DOI, Life Sci. Alliance 2022 DOI, Dev. Growth Diff. 2022 DOI)
EDUCATION
2022 Qualification for “Team management:”. Pasteur Institute of Lille, 8 specific modules and workshops “from individual to collective management” (Néom, Lyon), France.
2011 Accreditation for Research Direction (HDR), University of Lille: “Receptors Tyrosine Kinases: structural and functional approaches. Implications in metabolic diseases and oncogenesis”, Lille University, France.
2003 PhD « Receptors Tyrosine Kinases in the parasite Schistosoma mansoni » (option parasitology and molecular biology), Lille University, France.
2000 Master « Biology and Health » option immunology, Lille University, France.
CURRENT POSITION
Since 2022 Director of Research at CNRS working as group leader.
PREVIOUS POSITIONS
2009-2022 CNRS researcher, Pasteur Institute of Lille, France
2007-2009 Post-doc “Design of sugar-based c-MET inhibitors”, UMR8161 CNRS, Institut de Biologie de Lille, France.
2003-2007 Post-doc “Glucose transporters: SNAREs driven membrane fusion mechanisms”, SUNY at Stony Brook, New York, USA.
2000-2003 PhD at Center for Immunity and Parasite Biology (U547 INSERM), Institut Pasteur de Lille, France
FELLOWSHIPS AND AWARDS
2011 Grand Prize received from GEFLUC cancer foundation
2000-2003 CNRS PhD Fellowship
SELECTION OF FIVE RECENT PUBLICATIONS
| 1 | Mouton S, Mougel A, Ustyantsev K, Dissous C, Melnyk O, Berezikov E, Vicogne J. (2024) Optimized protocols for RNA interference in Macrostomum lignano. G3 (Bethesda). 2024. DOI Using our expertise in Schistosoma mansoni biology, we developed a cost-effective method for genetic interference in the flatworm Macrostomum lignano. |
| 2 | Girod V, Houssier R, Sahmer K, Ghoris MJ, Caby S, Melnyk O, Dissous C, Senez V, Vicogne J. (2022) A self-purifying microfluidic system for identifying drugs acting against adult schistosomes. R. Soc. Open Sci. 2022. DOI We designed the first microfluidic device allowing a fast selection of anti-schistosomicidal drugs in dynamic conditions. |
| 3 | De Nola G, Leclercq B, Mougel A, Taront S, Simonneau C, Forneris F, Adriaenssens E, Drobecq H, Iamele L, Dubuquoy L, Melnyk O, Gherardi E, de Jonge H, Vicogne J. (2022) Dimerization of kringle 1 domain from HGF/SF provides a potent MET receptor agonist. Life Sci. Alliance. 2022. DOI Using combinations of chemical and structural biology approaches, we designed of a potent c-MET agonist with broad applications in regenerative medicine. |
| 4 | Snella B, Grain B, Vicogne J, Capet F, Melnyk O, Agouridas V. (2022) Fast protein modification in the nanomolar concentration range using an oxalyl amide as latent thioester. Angew. Chem. Int. Ed. 2022. DOI Inspired by the very high reactivity of some cell metabolites, this work has potentially significant implications for the accelerated production of conjugates of medical interest. Hot Paper. |
| 5 | Leippe P, Broichhagen J, Cailliau K, Mougel A, Morel M, Dissous C, Trauner D, Vicogne J. (2020) Transformation of Receptor Tyrosine Kinases into Glutamate Receptors and Photoreceptors. Angew Chem. Int. Ed. 2020. DOI By mimicking the natural structure of the Venus Kinase Receptor and taking advantages photo-switchable glutamate ligands, we generate photo-activatable humanized tyrosine kinase chimeras. |